Icecure Medical (ICCM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
IceCure Medical’s ProSense® Cryoablation technology shows promise in treating kidney tumors with an 88.7% recurrence-free rate in patients unable to undergo surgery, based on interim results from the ICESECRET study. This innovative, minimally-invasive procedure is gaining traction globally, with approvals in major markets such as the U.S. and Europe. Investors might find the company’s progress appealing, especially as the demand for non-surgical cancer treatments grows.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Oppenheimer Pounds the Table on Coinbase Stock
- New “Anti-Woke” ETF Targets Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
